NVS - Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst | Benzinga
Thursday, Novartis AG (NYSE:NVS) decided to step back from pursuing the Cytokinetics Inc (NASDAQ:CYTK) acquisition, dealing a blow to the potential deal with the promising heart drug developer.
Analysts estimated Cytokinetics’ cardiomyopathy drug sales of up to $3.6 billion by 2032.
In December, Cytokinetics released topline results from the SEQUOIA-HCM Phase 3 trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), showing that treatment with aficamten significantly improved exercise capacity compared to placebo.
HC Wainwright acknowledges that Cytokinetics is a potential acquisition target, but ...